% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Schneider:141620,
author = {Schneider, Susanne A and Tahirovic, Sabina and Hardy, John
and Strupp, Michael and Bremova-Ertl, Tatiana},
title = {{D}o heterozygous mutations of {N}iemann-{P}ick type {C}
predispose to late-onset neurodegeneration: a review of the
literature.},
journal = {Journal of neurology},
volume = {268},
number = {6},
issn = {0340-5354},
address = {Berlin},
publisher = {Springer77118},
reportid = {DZNE-2020-07944},
pages = {2055-2064},
year = {2021},
abstract = {Monogenic diseases are important models for the study of
neurodegenerative diseases, such as Parkinson's disease (PD)
and dementia. Notably, for some disorders, homozygosity is
associated with a complex metabolic disease, while
heterozygosity predisposes to late-onset neurodegeneration.
For instance, biallelic glucocerebrosidase gene mutations
cause Gaucher's disease, while heterozygous mutations are a
common genetic risk factor for late-onset PD. Little is
known about similar risks of related diseases, such as
Niemann-Pick type C (NPC). Given that both conditions map
into related, i.e., lysosomal, pathways, we hypothesize a
similar risk of single-NPC gene mutations. Indeed, there is
increasing evidence based on clinical observations in humans
and animal studies. Here we review the current knowledge of
NPC heterozygosity.Family history studies suggest a high
proportion of late-onset neurodegenerative diseases in NPC
families. We identified 19 cases with heterozygous NPC
mutations in the literature who presented with a
neurodegenerative disease, including levodopa-responsive PD,
atypical parkinsonism (PSP, CBD), dystonia or dementia with
a mean age at onset of about 57 years (range 8-87).
Consistent splenomegaly and mildly abnormal filipin staining
results have also been reported in heterozygous gene
mutation carriers. Imaging and pathological data support
this notion.This finding has wider implications in so far as
NPC-related forms of Parkinsonian syndromes, dementia, motor
neuron disease and other neurodegenerative disorders may
benefit from NPC-mechanistic therapies, in particular
related to lysosomal dysfunction. Further research is
warranted to generate systematic data of heterozygous
mutation carriers, including longitudinal data.},
subtyp = {Review Article},
keywords = {Adolescent / Adult / Aged / Aged, 80 and over / Animals /
Child / Gaucher Disease / Glucosylceramidase: genetics /
Heterozygote / Humans / Middle Aged / Mutation /
Neurodegenerative Diseases: genetics / Niemann-Pick Disease,
Type C: genetics / Young Adult},
cin = {Pre 2020 / AG Tahirovic},
ddc = {610},
cid = {I:(DE-2719)999999 / I:(DE-2719)1140003},
pnm = {899H - Addenda (POF3-899H) / 352 - Disease Mechanisms
(POF4-352)},
pid = {G:(DE-HGF)POF3-899H / G:(DE-HGF)POF4-352},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31701332},
doi = {10.1007/s00415-019-09621-5},
url = {https://pub.dzne.de/record/141620},
}